KR102410733B1 - 헌팅틴 단백질을 영상화하기 위한 프로브 - Google Patents

헌팅틴 단백질을 영상화하기 위한 프로브 Download PDF

Info

Publication number
KR102410733B1
KR102410733B1 KR1020177007881A KR20177007881A KR102410733B1 KR 102410733 B1 KR102410733 B1 KR 102410733B1 KR 1020177007881 A KR1020177007881 A KR 1020177007881A KR 20177007881 A KR20177007881 A KR 20177007881A KR 102410733 B1 KR102410733 B1 KR 102410733B1
Authority
KR
South Korea
Prior art keywords
imidazo
pyridine
carbonitrile
methoxy
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177007881A
Other languages
English (en)
Korean (ko)
Other versions
KR20170047303A (ko
Inventor
셀리아 도밍게즈
존 휘트약
조나단 바드
알렉스 키셀료프
크리스토퍼 존 브라운
마이클 에드워드 프라임
피터 데이비드 존슨
다니엘 클락-프류
Original Assignee
씨에이치디아이 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨에이치디아이 파운데이션, 인코포레이티드 filed Critical 씨에이치디아이 파운데이션, 인코포레이티드
Publication of KR20170047303A publication Critical patent/KR20170047303A/ko
Application granted granted Critical
Publication of KR102410733B1 publication Critical patent/KR102410733B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020177007881A 2014-08-29 2015-08-28 헌팅틴 단백질을 영상화하기 위한 프로브 Active KR102410733B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
US62/043,590 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
KR20170047303A KR20170047303A (ko) 2017-05-04
KR102410733B1 true KR102410733B1 (ko) 2022-06-20

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007881A Active KR102410733B1 (ko) 2014-08-29 2015-08-28 헌팅틴 단백질을 영상화하기 위한 프로브

Country Status (20)

Country Link
US (2) US11104691B2 (enExample)
EP (1) EP3197277B1 (enExample)
JP (1) JP6754353B2 (enExample)
KR (1) KR102410733B1 (enExample)
CN (1) CN107105667B (enExample)
AU (2) AU2015308769A1 (enExample)
BR (1) BR112017004140B1 (enExample)
CA (1) CA2959533C (enExample)
DK (1) DK3197277T3 (enExample)
EA (1) EA039923B1 (enExample)
ES (1) ES2905095T3 (enExample)
HR (1) HRP20220001T1 (enExample)
HU (1) HUE057702T2 (enExample)
IL (1) IL250802B (enExample)
MX (1) MX386798B (enExample)
PL (1) PL3197277T3 (enExample)
PT (1) PT3197277T (enExample)
SG (1) SG11201701592SA (enExample)
SI (1) SI3197277T1 (enExample)
WO (1) WO2016033440A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
US20190381030A1 (en) * 2017-10-12 2019-12-19 University Of Kansas Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using yel002/bcn057
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
AU2020267664B2 (en) 2019-05-09 2023-04-27 F. Hoffmann-La Roche Ag Synthesis of labeled imidazo[1,2-A]pyrimidines
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065727A1 (en) 2008-03-21 2011-03-17 Sanofi-Aventis POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
US20110171739A1 (en) 2008-09-23 2011-07-14 Wista Laboratories Ltd. Ligands for aggregated tau molecules
WO2015044095A1 (en) 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2004265174A1 (en) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. Probe for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles.
EP2042501B1 (en) * 2006-06-21 2017-04-12 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
KR20090091287A (ko) * 2006-11-17 2009-08-27 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
NZ577511A (en) * 2006-11-30 2012-04-27 Nihon Mediphysics Co Ltd 2-Phenyl-imidazo[1,2-a]pyridine derivatives substituted with a radioactive halogen substituent
CA2676214A1 (en) * 2007-01-22 2008-07-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives
WO2009057577A1 (ja) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物の使用及び製造方法
WO2010011964A2 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
AU2012259929B2 (en) * 2011-05-20 2016-08-04 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5167436B2 (ja) * 2011-06-24 2013-03-21 日本メジフィジックス株式会社 新規アミロイド親和性化合物
JP2013237655A (ja) * 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
BR112015010469A2 (pt) * 2012-11-14 2017-07-11 Hoffmann La Roche derivados de imidazopiridina
SI2970255T1 (sl) 2013-03-14 2017-12-29 Galapagos Nv Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065727A1 (en) 2008-03-21 2011-03-17 Sanofi-Aventis POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
US20110171739A1 (en) 2008-09-23 2011-07-14 Wista Laboratories Ltd. Ligands for aggregated tau molecules
WO2015044095A1 (en) 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools

Also Published As

Publication number Publication date
US11104691B2 (en) 2021-08-31
SG11201701592SA (en) 2017-03-30
EP3197277B1 (en) 2021-12-22
JP6754353B2 (ja) 2020-09-09
WO2016033440A1 (en) 2016-03-03
HUE057702T2 (hu) 2022-05-28
IL250802B (en) 2020-08-31
IL250802A0 (en) 2017-04-30
CA2959533C (en) 2023-03-07
CN107105667A (zh) 2017-08-29
AU2015308769A1 (en) 2017-03-23
US11851446B2 (en) 2023-12-26
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
EP3197277A4 (en) 2018-04-18
EA201790400A1 (ru) 2017-09-29
EA039923B1 (ru) 2022-03-28
MX386798B (es) 2025-03-19
AU2019283999B2 (en) 2021-07-22
PL3197277T3 (pl) 2022-04-04
PT3197277T (pt) 2022-02-01
KR20170047303A (ko) 2017-05-04
JP2017529340A (ja) 2017-10-05
CN107105667B (zh) 2021-08-17
SI3197277T1 (sl) 2022-04-29
US20210380608A1 (en) 2021-12-09
BR112017004140A2 (pt) 2017-12-12
MX2017002702A (es) 2017-10-23
US20170283439A1 (en) 2017-10-05
AU2019283999A1 (en) 2020-01-23
CA2959533A1 (en) 2016-03-03
BR112017004140B1 (pt) 2023-01-10
ES2905095T3 (es) 2022-04-07
DK3197277T3 (da) 2022-01-31

Similar Documents

Publication Publication Date Title
US12258355B2 (en) Probes for imaging huntingtin protein
KR102410733B1 (ko) 헌팅틴 단백질을 영상화하기 위한 프로브
KR102410760B1 (ko) 헌팅틴 단백질을 영상화하기 위한 프로브
US11344637B2 (en) Probes for imaging huntingtin protein
EP3190888B1 (en) Probes for imaging huntingtin protein
HK1241224B (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1257113A1 (en) Probes for imaging huntingtin protein
HK1257113B (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200828

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211108

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220616

End annual number: 3

Start annual number: 1

PG1601 Publication of registration